Here’s Why Emergent BioSolutions (EBS) Became One of Carillon’s Worst Securities

Carillon Tower Advisers, an investment management firm, published its fourth quarter 2020 “Carillon Eagle Small Cap Growth Fund” investor letter – a copy of which can be downloaded here. In the letter, the fund talked about their best and worst securities, together with their outlook for this year from an investment perspective. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

Carillon Eagle Small Cap Growth Fund, in their Q4 2020 investor letter, mentioned Emergent BioSolutions Inc. (NYSE: EBS) and emphasized their views on the company. Emergent BioSolutions Inc. is a Rockville, Maryland-based specialty biopharmaceutical company that currently has a $4.9 billion market capitalization. Since the beginning of the year, EBS delivered a 3.60% return, impressively extending its 12-month gains to 61.89%. As of March 24, 2021, the stock closed at $90.85 per share.

Here is what Carillon Eagle Small Cap Growth Fund has to say about Emergent BioSolutions Inc. in their Q4 2020 investor letter:

“Emergent BioSolutions is a leading manufacturer of vaccines, therapeutics, and devices that are utilized to address public health threats. The firm’s main growth engine is their CDMO (contract development and manufacturing organization), which enabled them to reach manufacturing agreements with some of the major players in the COVID-19 vaccine rollout. Unfortunately, their main contracts are not with the two companies (Moderna and Pfizer) that already have vaccines that are approved and have begun distribution. These two leaders have set an extraordinarily high efficacy bar that has caused a number of later entrants to at least temporarily pause their own vaccine trials. This situation has pressured the stock as of late.”

Our calculations show that Emergent BioSolutions Inc. (NYSE: EBS) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Emergent BioSolutions Inc. was in 19 hedge fund portfolios, compared to 22 funds in the third quarter. EBS delivered a -1.34% return in the past 3 months.